Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

Phase 3

Terminated

• Conditions: Cystic Fibrosis

• Registration Number: NCT00125346
• Lead Sponsor: Novartis

Brief Summary

Lung infections are a chronic problem for patients with cystic fibrosis (CF). Some patients with CF may have a type of bacteria called Pseudomonas aeruginosa in their lungs that can cause infections or make their symptoms worse. Tobramycin inhalation solution (TOBI) is an approved antibiotic, which is inhaled directly into the lungs, and can be used to manage these infections. Tobramycin inhalation powder (TIP) is a new, experimental powder formulation of tobramycin that is inhaled directly into the lungs using a T-326 inhaler. The purpose of this research study is to determine if TIP is safe and effective when compared to placebo (a powder with no medicine) treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-07-28
• Study First Submitted QC: 2005-07-28
• Study First Posted: 2005-08-01
• Study Start: 2005-09
• Primary Completion: 2007-02
• Study Completion: 2007-02
• Status Verified: 2011-10
• Last Update Submitted: 2011-10-10
• Last Update Posted: 2011-10-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

• Confirmed diagnosis of cystic fibrosis patients with Pseudomonas aeruginosa infection.
• Male and female subjects between 6 and 21 years of age at the time of screening.
• FEV1 at screening must be between 25% and 80% of normal predicted values.

Exclusion Criteria

• Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Forced expiratory volume in 1 second (FEV1) measured at week 1 and week 5.

Secondary Outcome Measures

Name	Time	Method
Time until first antipseudomonal antibiotic (an antibiotic used to treat bacteria of a certain type [the genus pseudomonas]) is used
Relative changes in FEV1 % predicted for patients who received TIP starting at visit 1 and for patients who received placebo starting at week 9, compared to all subsequent visits.
Relative change in FEV1 % predicted for patients who received placebo from week 5 to week 13
Relative change in FEV1 % predicted for patients who received placebo (from the average of four assessments [weeks 1, 2, 5, and 9] to week 13)
Change from baseline in susceptibility of pseudomonas to the antibiotic during the study measured at weeks 5, 9, 13, 17, 21, and 25, and change from baseline in quantity of pseudomonas found in sputum during the study measured at weeks 5, 9, 13, 17, 21,

Trial Locations

Locations (1)

For information on a site near you, call 1-800-244-7668 Option "2"; 🇲🇽 Tijuana, Mexico